Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRO-PET
2023-503686-26-00Phase 2Withdrawn
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Mar 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18F]-FAPI-74 in pulmonary fibrosis (PF), sponsored by St. Antonius Ziekenhuis. Primary endpoint: FAPI activity concentration in patients with predominant active fibrosis and predominant inflammation. Planned start Mar 2024; status: withdrawn.
02
Drugs
[18F]-FAPI-74
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2023-503686-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503686-26-00.